• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用组成型活性雌激素受体探究雌激素受体激活的机制:与DNA和共调节因子相互作用及受体构象变化的相关性

Mechanistic aspects of estrogen receptor activation probed with constitutively active estrogen receptors: correlations with DNA and coregulator interactions and receptor conformational changes.

作者信息

Lazennec G, Ediger T R, Petz L N, Nardulli A M, Katzenellenbogen B S

机构信息

Department of Molecular and Integrative Physiology, University of Illinois, Urbana 61801, USA.

出版信息

Mol Endocrinol. 1997 Aug;11(9):1375-86. doi: 10.1210/mend.11.9.9983.

DOI:10.1210/mend.11.9.9983
PMID:9259327
Abstract

The estrogen receptor (ER) belongs to a large family of nuclear receptors, many of whose members function as ligand-dependent transcriptional activators. The mechanism by which the receptor is converted from an inactive into an activated state is not yet completely understood. To investigate the kind of changes in receptor conformation and interactions that are involved in this activation, we have used the wild type ER and a set of constitutively active ER point mutants that show from 20% to nearly 100% activity in the absence of estrogen. These mutants are of particular interest as they could mimic, in the absence of ligand, the activated state of the wild type receptor. We have analyzed several transcriptional steps that could be involved in the activation: the ability of these receptors 1) to interact with several coactivators (steroid receptor coactivator-1, SRC-1; transcription intermediary factor-1, TIF-1; and estrogen receptor-associated protein 140, ERAP 140) and with members of the preinitiation complex [TATA box-binding protein (TBP), transcription factor IIB (TFIIB)]; 2) to exhibit conformational changes revealed by proteolytic digest patterns similar to those observed for the wild type hormone-occupied ER; and 3) to bend estrogen response element-containing DNA, which is thought to be one of the important phenomena triggering transcriptional activation. Our results demonstrate that the interaction of these mutant receptors with coactivators is likely to be one of the features of the activated step, as the mutant receptors interacted with some coactivators in a ligand-independent manner in proportion to their extent of constitutive activity. However, the different degrees of ligand-independent interaction of the mutant ERs with the three coactivators suggest that SRC-1, TIF-1, and ERAP 140 may play different roles in receptor activity. Limited proteolytic digest experiments reveal that the activated state of the receptor corresponds to a particular conformation of the receptor, which is fully observed with the mutant ER showing the highest activity in the absence of estrogen. Finally, it appears that in inactive or active states, the receptor exhibits distinctly different DNA-bending abilities. Addition of estradiol is able to modify the bending ability of only the wild type receptor, whereas estradiol has no influence on the constitutive receptors, which exhibited the same bending ability as that observed for the ligand-occupied wild type receptor. These data document that the ER undergoes major changes in its conformation and also in its functional properties when it is turned from an inactive into an active state and that mutational changes in the ER protein that result in constitutive, hormone-independent activation mimic many of the changes in ER properties that are normally under hormone regulation.

摘要

雌激素受体(ER)属于核受体大家族,其中许多成员作为配体依赖性转录激活因子发挥作用。受体从无活性状态转变为激活状态的机制尚未完全明了。为了研究这种激活过程中受体构象和相互作用的变化类型,我们使用了野生型ER和一组组成型激活的ER点突变体,这些突变体在无雌激素的情况下表现出20%至近100%的活性。这些突变体特别引人关注,因为它们在无配体的情况下可以模拟野生型受体的激活状态。我们分析了激活过程中可能涉及的几个转录步骤:这些受体1)与几种共激活因子(类固醇受体共激活因子-1,SRC-1;转录中介因子-1,TIF-1;以及雌激素受体相关蛋白140,ERAP 140)和起始前复合物成员[TATA盒结合蛋白(TBP)、转录因子IIB(TFIIB)]相互作用的能力;2)表现出蛋白水解消化模式所揭示的构象变化,类似于野生型激素占据的ER所观察到的变化;3)使含雌激素反应元件的DNA弯曲的能力,这被认为是触发转录激活的重要现象之一。我们的结果表明,这些突变体受体与共激活因子的相互作用可能是激活步骤的特征之一,因为突变体受体与一些共激活因子以配体非依赖性方式相互作用,其程度与它们的组成型活性程度成正比。然而,突变型ER与三种共激活因子的不同程度的配体非依赖性相互作用表明,SRC-1、TIF-1和ERAP 140可能在受体活性中发挥不同作用。有限的蛋白水解消化实验表明,受体的激活状态对应于受体的一种特定构象,在无雌激素时活性最高的突变型ER中能充分观察到这种构象。最后,似乎在无活性或活性状态下,受体表现出明显不同的DNA弯曲能力。添加雌二醇仅能改变野生型受体的弯曲能力,而雌二醇对组成型受体没有影响,组成型受体表现出与配体占据的野生型受体相同的弯曲能力。这些数据证明,当ER从无活性状态转变为活性状态时,其构象和功能特性会发生重大变化,并且ER蛋白中的突变变化导致组成型、激素非依赖性激活,模拟了许多通常受激素调节的ER特性变化。

相似文献

1
Mechanistic aspects of estrogen receptor activation probed with constitutively active estrogen receptors: correlations with DNA and coregulator interactions and receptor conformational changes.用组成型活性雌激素受体探究雌激素受体激活的机制:与DNA和共调节因子相互作用及受体构象变化的相关性
Mol Endocrinol. 1997 Aug;11(9):1375-86. doi: 10.1210/mend.11.9.9983.
2
Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein.在受体蛋白中含有针对酪氨酸537的氨基酸替代的组成型活性人雌激素受体。
Mol Endocrinol. 1996 Nov;10(11):1388-98. doi: 10.1210/mend.10.11.8923465.
3
Isoform-selective interactions between estrogen receptors and steroid receptor coactivators promoted by estradiol and ErbB-2 signaling in living cells.在活细胞中,雌二醇和ErbB-2信号传导促进雌激素受体与类固醇受体共激活因子之间的亚型选择性相互作用。
Mol Endocrinol. 2003 Apr;17(4):589-99. doi: 10.1210/me.2002-0351. Epub 2003 Jan 16.
4
Titration by estrogen receptor activation function-2 of targets that are downstream from coactivators.通过共激活因子下游的靶标的雌激素受体激活功能-2进行滴定。
Mol Endocrinol. 1999 Jun;13(6):897-909. doi: 10.1210/mend.13.6.0283.
5
Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction.组成型活性雌激素受体的配体结合特性改变及稳定性增强:证明配体相互作用需要开放口袋构象。
Biochemistry. 1997 Dec 2;36(48):14897-905. doi: 10.1021/bi971746l.
6
Different classes of coactivators recognize distinct but overlapping binding sites on the estrogen receptor ligand binding domain.不同类别的共激活因子识别雌激素受体配体结合域上不同但重叠的结合位点。
J Biol Chem. 1998 Oct 23;273(43):28371-7. doi: 10.1074/jbc.273.43.28371.
7
Estrogen response element-dependent regulation of transcriptional activation of estrogen receptors alpha and beta by coactivators and corepressors.共激活因子和共抑制因子对雌激素受体α和β转录激活的雌激素反应元件依赖性调控。
J Mol Endocrinol. 2004 Oct;33(2):387-410. doi: 10.1677/jme.1.01541.
8
Ligand-independent interactions of p160/steroid receptor coactivators and CREB-binding protein (CBP) with estrogen receptor-alpha: regulation by phosphorylation sites in the A/B region depends on other receptor domains.p160/类固醇受体共激活因子与CREB结合蛋白(CBP)和雌激素受体α的非配体依赖性相互作用:A/B区域磷酸化位点的调节取决于其他受体结构域。
Mol Endocrinol. 2003 Jul;17(7):1296-314. doi: 10.1210/me.2001-0316. Epub 2003 Apr 24.
9
Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer.在人类乳腺癌中,β-雌二醇和4-羟基他莫昔芬对共调节蛋白类固醇受体共激活因子-1以及维甲酸和甲状腺受体沉默介质向雌激素受体-雌激素反应元件的差异性募集作用
J Clin Endocrinol Metab. 2004 Jan;89(1):375-83. doi: 10.1210/jc.2003-031048.
10
A fusion protein of the estrogen receptor (ER) and nuclear receptor corepressor (NCoR) strongly inhibits estrogen-dependent responses in breast cancer cells.雌激素受体(ER)与核受体辅阻遏物(NCoR)的融合蛋白可强烈抑制乳腺癌细胞中雌激素依赖性反应。
Mol Endocrinol. 1999 Dec;13(12):2122-36. doi: 10.1210/mend.13.12.0394.

引用本文的文献

1
Decoding estrogen receptor and GPER biology: structural insights and therapeutic advances in ERα-positive breast cancer.解析雌激素受体和G蛋白偶联雌激素受体生物学:雌激素受体α阳性乳腺癌的结构见解与治疗进展
Front Oncol. 2025 Jun 26;15:1513225. doi: 10.3389/fonc.2025.1513225. eCollection 2025.
2
Development of PROTACs targeting estrogen receptor: an emerging technique for combating endocrine resistance.靶向雌激素受体的PROTACs的开发:一种对抗内分泌抵抗的新兴技术。
RSC Med Chem. 2024 Dec 30. doi: 10.1039/d4md00961d.
3
Estrogen Receptor Alpha and ESR1 Mutations in Breast Cancer.
乳腺癌中的雌激素受体 alpha 和 ESR1 突变。
Adv Exp Med Biol. 2022;1390:171-194. doi: 10.1007/978-3-031-11836-4_10.
4
Dynamic molecular evolution of a supergene with suppressed recombination in white-throated sparrows.具有抑制重组的超级基因在白喉雀中的动态分子进化。
Elife. 2022 Aug 30;11:e79387. doi: 10.7554/eLife.79387.
5
Inside the supergene of the bird with four sexes.在具有四种性别的鸟类的超级基因内。
Horm Behav. 2020 Nov;126:104850. doi: 10.1016/j.yhbeh.2020.104850. Epub 2020 Sep 19.
6
A supergene-linked estrogen receptor drives alternative phenotypes in a polymorphic songbird.一个超级基因连锁的雌激素受体驱动一个多态鸣禽的替代表型。
Proc Natl Acad Sci U S A. 2020 Sep 1;117(35):21673-21680. doi: 10.1073/pnas.2011347117. Epub 2020 Aug 17.
7
Suppression of breast cancer metastasis and extension of survival by a new antiestrogen in a preclinical model driven by mutant estrogen receptors.新型抗雌激素在突变雌激素受体驱动的临床前模型中抑制乳腺癌转移和延长生存时间。
Breast Cancer Res Treat. 2020 Jun;181(2):297-307. doi: 10.1007/s10549-020-05629-y. Epub 2020 Apr 10.
8
Proteomic profiling identifies key coactivators utilized by mutant ERα proteins as potential new therapeutic targets.蛋白质组学分析鉴定了突变型 ERα 蛋白所利用的关键共激活因子,这些因子可能成为新的治疗靶点。
Oncogene. 2018 Aug;37(33):4581-4598. doi: 10.1038/s41388-018-0284-2. Epub 2018 May 11.
9
Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance.雌激素受体突变在内分泌治疗耐药中的结构基础。
Nat Rev Cancer. 2018 Jun;18(6):377-388. doi: 10.1038/s41568-018-0001-z.
10
Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors.结构新颖的抗雌激素对乳腺癌细胞和肿瘤中组成型活性突变雌激素受体产生不同反应。
Cancer Res. 2017 Oct 15;77(20):5602-5613. doi: 10.1158/0008-5472.CAN-17-1265. Epub 2017 Sep 13.